Research Topics
Genomes and GenesSpecies | Tomas KirchhoffSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
BRCA mutations and risk of prostate cancer in Ashkenazi JewsTomas Kirchhoff
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 10:2918-21. 2004..Several series looking at the frequency of BRCA mutations in unselected patients with prostate cancer have not confirmed this finding. To clarify this issue, we conducted a large case-control study...
The 6q22.33 locus and breast cancer susceptibilityTomas Kirchhoff
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Cancer Epidemiol Biomarkers Prev 18:2468-75. 2009..Further functional studies of candidate genes are in progress, and a large replication analysis is being completed as part of an international consortium...- Germline BRCA mutations denote a clinicopathologic subset of prostate cancerDavid J Gallagher
Clinical Genetics Service, Department of Medicine, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 16:2115-21. 2010..Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined... - Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mappingNathan A Ellis
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Genet Epidemiol 30:48-61. 2006..While these results demonstrate the feasibility of genome-wide association strategies, further application of this approach will critically depend on optimizing the density and distribution of SNPs and the size and type of study design... 
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2Tomas Kirchhoff
Memorial Sloan Kettering Cancer Center MSKCC Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America TK, MG, KO Department of Environmental Medicine, New York University Cancer Institute, New York University, New York, New York, United States of America TK, American Cancer Society, Atlanta, Georgia, United States of America MG
PLoS ONE 7:e35706. 2012..89, 95%CI 0.80-1.00, p = 0.048), indicating a potential protective effect of this allele. These data suggest that that 6q22.33 confers a weak effect on breast cancer risk...- Common genetic variants and modification of penetrance of BRCA2-associated breast cancerMia M Gaudet
Department of Epidemiology and Population Health and Department of Obstetrics and Gynecology and Women s Health, Albert Einstein College of Medicine, New York, New York, United States of America
PLoS Genet 6:e1001183. 2010..28, 95% CI 1.18-1.39, ). These results indicate that SNPs that modify BRCA2 penetrance identified by an agnostic approach thus far are limited to variants that also modify risk of sporadic BRCA2 wild-type breast cancer... - Analysis of genetic variation in Ashkenazi Jews by high density SNP genotypingAdam B Olshen
Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BMC Genet 9:14. 2008..435,632 SNPs overlapped and met annotation criteria in the two groups... - Localization of cancer susceptibility genes by genome-wide single-nucleotide polymorphism linkage-disequilibrium mappingNandita Mitra
Department of Epidemiology and Biostatistics, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 64:8116-25. 2004..This work demonstrates the power of the LD mapping approach in an isolated population and its general applicability to the identification of novel cancer-causing genes... - Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancerTomas Kirchhoff
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Natl Cancer Inst 96:68-70. 2004..22 to 1.14). We thus recommend that counseling for colorectal cancer screening and prevention in individuals with BRCA mutations be based on the personal and family history of colorectal cancer or associated syndromic malignancies... - A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencingLiying Zhang
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Mol Diagn 11:176-81. 2009..We show that pyrosequencing is a rapid and reliable method that serves as an excellent platform for BRCA founder mutation analysis, especially when only paraffin-embedded tissues are available... - A636P is associated with early-onset colon cancer in Ashkenazi JewsJose G Guillem
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Am Coll Surg 196:222-5. 2003..This study seeks to characterize the proportion of individuals of Ashkenazi heritage with very early-onset colon cancer (diagnosed at age 40 or younger) that could be attributed to MSH2*1906C>G... - Susceptibility loci associated with prostate cancer progression and mortalityDavid J Gallagher
Department of Medicine, Clinical Genetics Service, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Albert Einstein College of Medicine, New York, New York 10065, USA
Clin Cancer Res 16:2819-32. 2010..Prostate cancer is a heterogeneous disease with a variable natural history that is not accurately predicted by currently used prognostic tools... - Genome-wide association studies of cancer predispositionZsofia K Stadler
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Hematol Oncol Clin North Am 24:973-96. 2010..Studies involving more heterogeneous populations, determination of the causal variants, and functional studies are now necessary to further elucidate the potential biologic and clinical significance of the observed associations... - Frequency of CHEK2*1100delC in New York breast cancer cases and controlsKenneth Offit
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BMC Med Genet 4:1. 2003..While the frequency of 1100delC was 1.1-1.4% in healthy Finnish controls, the frequency of this allele in a North American control population and in North American breast cancer kindreds remains unclear... - The signatures of autozygosity among patients with colorectal cancerManny D Bacolod
Department of Microbiology, Weill Medical College of Cornell University, New York, NY 10021, USA
Cancer Res 68:2610-21. 2008.... - Susceptibility loci associated with specific and shared subtypes of lymphoid malignanciesJoseph Vijai
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
PLoS Genet 9:e1003220. 2013..These results, showing novel susceptibility regions and allelic heterogeneity, point to the existence of pathways of susceptibility to both shared as well as specific subtypes of lymphoid malignancy...